The findings confirm that allosteric inhibition of integrase is clinically viable, validating a new antiviral drug class.

A federal grant for HIV research is part of $15.7 million the National Institutes for Health awarded to the Wertheim UF ...

There’s been a lot of grim news lately about HIV and AIDS: Rising infections among high-risk U.S. communities, continued risk behaviors, and plague-level infection rates across sub-Saharan Africa. In ...

The drug can be produced for as little as $25 per person annually, but even at $2000 per person, it can reduce new US infections almost entirely, a researcher says.

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported Wednesday. In clinical trials, the drug nearly eliminated HIV’s spread among ...

Cabotegravir was already approved for use in England and Wales as part of a combination treatment for people living with HIV.

DUBLIN--(BUSINESS WIRE)--The "HIV Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for HIV Drugs was valued at US$32.8 Billion in ...